The European specialty pharma M&A landscape is undergoing significant transformations, with private equity firms facing new and unprecedented challenges.

In 2024, the rare and orphan disease market has become a focal point for mergers and acquisitions (M&A) in the pharmaceutical industry.Pharmaceutical companies are increasingly targeting this sector, driven by a combination of various incentives. This white paper...

Leveraging Non-Invasive Testing in CNS and Transplant Rejection: Ongoing Research and Early Pharma Partnerships Drive Diagnostic Innovations.

With deal volumes holding steady compared to Q1 2023 we may be seeing a bottoming out of ageneral decline. Companies utilising AI, oncology and CNS are all still areas of significant activity.

Diagnostics (Dx) is a key component in the healthcare sector, especially within oncology where the increasing need for personalised medicine and companion diagnostics is driving dealmaking.

With recent approvals of expensive personalised and targeted therapies the pressure to make these available to patients where the impact will be most effective is increasing. Diagnostics have a key role to play and this quarter we notice an increase in diagnostics...

In 2023, the diagnostics sector saw over 430 Dx-related transactions, averaging approximately 110 deals per quarter. USA and North America generally dominated the deal space, with 68% of sellers and 61% of buyers. European engagement was lower, with 24% and 30%...

Despite concerns around the global political and economic landscape, the biopharmaceutical industry still maintains a favourable mid-to long-term outlook with a promising future for revenues. The industry’s clinical pipeline remains robust, with a growing number of...

Contract Development & Manufacturing Organisations (CDMOs) increasingly need to differentiate and establish their competitive advantage to effectively cater to the growing demand and to enhance their profitability. There is a greater demand for CDMOs offering...

Whilst the Biosimilars market represents a massive commercial opportunity, the landscape is quite complex, with multiple dynamics at play. Competition is high, and research proves that there is a strong correlation between market entry order and market uptake. How do...

To remain competitive and to take advantage of the latest innovations, life science companies can’t afford to ignore opportunities in South Korea. PharmaVentures has successfully completed over 30 projects for South Korean...

More important than ever, but there’s still a way to go. Just the other week, it was announced that Illumina had acquired GRAIL (subject to approval from the regulators), a company it formed in 2016 and spun out. Illumina retained a 12% stake in the business and has...

Getting your opportunity noticed by a large pharmaceutical company is difficult, as they are continually bombarded by partnering opportunities daily. PharmaVentures has developed a unique expertise in getting their clients’ opportunities through the complex processes...

NSCLC is one of the most active areas of innovation in Oncology, and recent consensus estimates indicate that an additional $20BN of sales could be added in the indication over the next few years.

In the Spring of 2020, during the early days of the COVID-19 pandemic when there were real fears of a global downturn, PharmaVentures predicted that despite the forthcoming challenges, licensing and partnering would remain steady during 2020. With the year behind us,...

The last few years have seen a rise in nationalism and populism across the world. In 2016, the US voted in the populist Donald Trump on his promise to ‘Make America Great Again’. In 2018, Hungary re-elected its national conservative prime minister Viktor Orbán with...

Even though medical diagnosis can be traced back to ancient Egypt in the 26th century BC (Edwin Smith Papyrus by Imhotep), in vitro diagnostics (IVD) as a field really started to take shape from late 20th century. Significant investments and research have been...

At PharmaVentures, a data room is used as a location to store essential documents that are needed during an M&A or Divestment transaction. It is an essential part of the due diligence process which interested buyers access prior to closing a transaction. We...

Haematological malignancies are types of cancers affecting blood, bone marrow and lymph nodes. Broadly speaking, there are three major types of blood cancers: leukaemia, lymphoma and myeloma. Of these, the most common blood cancer types include non-Hodgkin lymphoma...

As you are aware PharmaVentures is a sector focused advisory firm and we are at the forefront of deal-making activity in the pharmaceutical, biotech, medtech and service sector industries such as CROs and CDMOs. Given the current backdrop and challenges facing...

There is strong appetite for cross-border transactions between China and the rest of the world. Improved overall market environment will encourage attractive deal terms and future market potential. Selecting the right partner and effective communication are...

This is the first in a series of white papers by the experts at PharmaVentures that explores the challenges of valuing drug candidates at various stages of clinical development. This series is based on the experiences we have encountered using valuation in actual...

In the recent years, the level of interest in Gene Therapy from both industry and academia has been unparalleled. CNS disorders in particular have gained a lot of attention with a considerable emphasis on neurological targets; and this is especially visible when...

Barely a month passes without an announcement of improved survival rates for non-small cell lung cancer (NSCLC) patients. Much of this has been driven by favouring a personalised medicine approach over the historic “one size fits all” chemotherapy paradigm. Drugs...

Despite the impressive growth observed in China over the last two decades and with a projected healthcare market of RMB 8 trillion (USD 1.2 trillion), Chinese life science companies lag behind toptiered Western counterparts, both in terms of market capitalisation and...

On May 26th 2017, a new set of European Medical Device Regulations (“MDR”) and In Vitro Diagnostic Regulations (“IVDR”) entered into force. They represent a major overhaul and tightening of the previous directives and affect all companies marketing or developing...

Today the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching $200 Billion, the bulk of which is accounted for by sales of the four leading agents.

The term Nanotechnology refers to the domain of science and engineering that is applied to structures and materials that measure only a few billionths of a meter.  The term was coined by Japanese scientist Norio Taniguchi almost 40 years ago, and then popularised...

It’s easy to find trading and M&A multiples for mid and top tier CROs as their financial data are plentiful, often in the public domain and are the subject of discussion both in print and at conferences globally.  Although consolidation in this sector is often...

Pain management continues to face the dual hurdles of abuse of the most efficacious (opiod based) therapies and the difficulties of developing and commercialising new treatments. This challenging environment presents difficulties both for large pharmaceutical...